C Krishna Prasad, Managing Director (MD) of Granules India said with only three to four main competitors in the US market, the company‘s topline and bottomline will benefit from the drug.
first published: Sep 28, 2015 12:48 pm
A collection of the most-viewed Moneycontrol videos.
Rupee Slide Weighs Heavy As Nifty Tests 25,900| Midcaps See Sharp Cuts| Closing Bell Live
Meesho's Rs 5,421 Cr IPO Kicks Off| Post-IPO Playbook, Profitability Path & More| IPO Watch Live
Can Nifty Hold Above 26,000 Amid Currency Jitters? Meesho IPO Opens | Opening Bell Live
Nifty Struggles Below 26,100 On Weekly F&O Expiry As Rupee Hits New Low| Closing Bell Live
